GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Other Long Term Assets

Diamyd Medical AB (FRA:DMN) Other Long Term Assets : €0.74 Mil (As of Feb. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Other Long Term Assets?

Diamyd Medical AB's other long-term assets for the quarter that ended in Feb. 2025 was €0.74 Mil.

Diamyd Medical AB's quarterly other long-term assets declined from Aug. 2024 (€0.75 Mil) to Nov. 2024 (€0.73 Mil) but then increased from Nov. 2024 (€0.73 Mil) to Feb. 2025 (€0.74 Mil).

Diamyd Medical AB's annual other long-term assets declined from Aug. 2022 (€1.69 Mil) to Aug. 2023 (€1.07 Mil) and declined from Aug. 2023 (€1.07 Mil) to Aug. 2024 (€0.75 Mil).

Diamyd Medical AB Other Long Term Assets Historical Data

The historical data trend for Diamyd Medical AB's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Other Long Term Assets Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 3.22 1.69 1.07 0.75

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.76 0.75 0.73 0.74

Diamyd Medical AB Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Other Long Term Assets
Comparable Companies
XSAT:HAMLET B OSTO:IBT B OSTO:SYNACT OSTO:SANION OSTO:MAGLE OSTO:FLUO OSTO:ONCO OSTO:CANTA OSTO:INIT OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
DYMDF:USA DMYD B:Sweden
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.